Emphysema - Pipeline Review, H1 2012

Global Markets Direct, May 2012, Pages: 33

Emphysema – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Emphysema - Pipeline Review, H1 2012', provides an overview of the Emphysema therapeutic pipeline. This report provides information on the therapeutic development for Emphysema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Emphysema. 'Emphysema - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Emphysema.
- A review of the Emphysema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Emphysema pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Emphysema.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Emphysema pipeline depth and focus of Emphysema therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Emphysema Therapeutic Products under Development, Key Players in Emphysema Therapeutics, Emphysema Pipeline Overview, Emphysema Pipeline, Emphysema Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Emphysema Overview
Therapeutics Development
An Overview of Pipeline Products for Emphysema
Emphysema Therapeutics under Development by Companies
Emphysema Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Emphysema Therapeutics – Products under Development by Companies
Emphysema Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Emphysema Therapeutics Development
GTC Biotherapeutics, Inc.
Kamada Ltd.
Emphysema – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Aerosolized AAT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mesenchymal Stromal Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Emphysema Therapeutics – Drug Profile Updates
Emphysema Therapeutics - Dormant Products
Emphysema – Product Development Milestones
Featured News & Press Releases
Mar 02, 2012: Mylan Continues To Pursue Damages And Injunction Against Sunovion's Brovana In Ongoing Litigation
Jun 13, 2011: MEDIPOST Acquires Patent For Pneumostem
Mar 23, 2011: Novartis Announces FDA Extension For Regulatory Review Period For QAB149
Aug 26, 2010: Baxter International Inc. acquires exclusive right to distribute Kamada’s Glassi alpha-1 augmentation therapy in Canada
Feb 09, 2010: Kamada Commences Enrollment In European Inhaled AAT Clinical Trial For Alpha-1 Antitrypsin Deficiency
Feb 08, 2010: Kamada Announces Enrollment of First Patient in Its Pivotal Study for Inhaled AAT in Europe
Sep 16, 2009: Kamada Presents Data On Inhaled Alpha-1 Antitrypsin In Cystic Fibrosis Patients At The European Respiratory Society Meeting 2009, Vienna
May 01, 2008: Sepracor And Arrow Sign Global License And Development Agreement Covering Technology To Enhance Ciclesonide And Brovana Franchises
Nov 05, 2007: Sepracor Announced the Establishment of a Unique Product-Specific Billing Code (or J-Code) for Brovana
Apr 11, 2007: Sepracor's Brovana Inhalation Solution Launched In The United States for Patients with Chronic Obstructive Pulmonary Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Emphysema, H1 2012
Products under Development for Emphysema – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
GTC Biotherapeutics, Inc., H1 2012
Kamada Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Emphysema Therapeutics – Drug Profile Updates
Emphysema Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Emphysema, H1 2012
Products under Development for Emphysema – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Emphysema Global Clinical Trials Review, H2, 2012
• Emphysema - Pipeline Review, H2 2011
• Emphysema Global Clinical Trials Review, H2, 2011
• Emphysema - Pipeline Review, Q2 2011
• Alzheimer's Disease – Pipeline Review, H1 2013
• Bronchiectasis - Pipeline Review, H1 2013
• Cystic Fibrosis - Pipeline Review, H1 2013
• Chronic Bronchitis - Pipeline Review, H1 2013
• Osteoporosis - Pipeline Review, H1 2013
• Obstructive Pulmonary Disease - Pipeline Review, H2 2012